Glial fibrillary acidic protein, neurofilament light, matrix metalloprotease 3 and fatty acid binding protein 4 as non-invasive brain tumor biomarkers.

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS

ACS Applied Bio Materials Pub Date : 2024-06-15 DOI:10.1186/s12014-024-09492-7

Atefeh Ghorbani, Miyo K Chatanaka, Lisa M Avery, Mingyue Wang, Jermaine Brown, Rachel Cohen, Taron Gorham, Salvia Misaghian, Nikhil Padmanabhan, Daniel Romero, Martin Stengelin, Anu Mathew, George Sigal, Jacob Wohlstadter, Craig Horbinski, Katy McCortney, Wei Xu, Gelareh Zadeh, Alireza Mansouri, George M Yousef, Eleftherios P Diamandis, Ioannis Prassas

{"title":"Glial fibrillary acidic protein, neurofilament light, matrix metalloprotease 3 and fatty acid binding protein 4 as non-invasive brain tumor biomarkers.","authors":"Atefeh Ghorbani, Miyo K Chatanaka, Lisa M Avery, Mingyue Wang, Jermaine Brown, Rachel Cohen, Taron Gorham, Salvia Misaghian, Nikhil Padmanabhan, Daniel Romero, Martin Stengelin, Anu Mathew, George Sigal, Jacob Wohlstadter, Craig Horbinski, Katy McCortney, Wei Xu, Gelareh Zadeh, Alireza Mansouri, George M Yousef, Eleftherios P Diamandis, Ioannis Prassas","doi":"10.1186/s12014-024-09492-7","DOIUrl":null,"url":null,"abstract":"Background: Gliomas are aggressive malignant tumors, with poor prognosis. There is an unmet need for the discovery of new, non-invasive biomarkers for differential diagnosis, prognosis, and management of brain tumors. Our objective is to validate four plasma biomarkers - glial fibrillary acidic protein (GFAP), neurofilament light (NEFL), matrix metalloprotease 3 (MMP3) and fatty acid binding protein 4 (FABP4) - and compare them with established brain tumor molecular markers and survival.Methods: Our cohort consisted of patients with benign and malignant brain tumors (GBM = 77, Astrocytomas = 26, Oligodendrogliomas = 23, Secondary tumors = 35, Meningiomas = 70, Schwannomas = 15, Pituitary adenomas = 15, Normal individuals = 30). For measurements, we used ultrasensitive electrochemiluminescence multiplexed immunoassays.Results: High plasma GFAP concentration was associated with GBM, low GFAP and high FABP4 were associated with meningiomas, and low GFAP and low FABP4 were associated with astrocytomas and oligodendrogliomas. NEFL was associated with progression of disease. Several prognostic genetic alterations were significantly associated with all plasma biomarker levels. We found no independent associations between plasma GFAP, NEFL, FABP4 and MMP3, and overall survival. The candidate biomarkers could not reliably discriminate GBM from primary or secondary CNS lymphomas.Conclusions: GFAP, NEFL, FABP4 and MMP3 are useful for differential diagnosis and prognosis, and are associated with molecular changes in gliomas.","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11179213/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12014-024-09492-7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Gliomas are aggressive malignant tumors, with poor prognosis. There is an unmet need for the discovery of new, non-invasive biomarkers for differential diagnosis, prognosis, and management of brain tumors. Our objective is to validate four plasma biomarkers - glial fibrillary acidic protein (GFAP), neurofilament light (NEFL), matrix metalloprotease 3 (MMP3) and fatty acid binding protein 4 (FABP4) - and compare them with established brain tumor molecular markers and survival.

Methods: Our cohort consisted of patients with benign and malignant brain tumors (GBM = 77, Astrocytomas = 26, Oligodendrogliomas = 23, Secondary tumors = 35, Meningiomas = 70, Schwannomas = 15, Pituitary adenomas = 15, Normal individuals = 30). For measurements, we used ultrasensitive electrochemiluminescence multiplexed immunoassays.

Results: High plasma GFAP concentration was associated with GBM, low GFAP and high FABP4 were associated with meningiomas, and low GFAP and low FABP4 were associated with astrocytomas and oligodendrogliomas. NEFL was associated with progression of disease. Several prognostic genetic alterations were significantly associated with all plasma biomarker levels. We found no independent associations between plasma GFAP, NEFL, FABP4 and MMP3, and overall survival. The candidate biomarkers could not reliably discriminate GBM from primary or secondary CNS lymphomas.

Conclusions: GFAP, NEFL, FABP4 and MMP3 are useful for differential diagnosis and prognosis, and are associated with molecular changes in gliomas.

查看原文本刊更多论文

作为非侵入性脑肿瘤生物标志物的胶质纤维酸性蛋白、神经丝蛋白、基质金属蛋白酶 3 和脂肪酸结合蛋白 4。

背景：胶质瘤是侵袭性恶性肿瘤，预后不良。在脑肿瘤的鉴别诊断、预后和管理方面，发现新的非侵入性生物标志物的需求尚未得到满足。我们的目的是验证四种血浆生物标记物--胶质纤维酸性蛋白（GFAP）、神经丝光（NEFL）、基质金属蛋白酶3（MMP3）和脂肪酸结合蛋白4（FABP4）--并将它们与已有的脑肿瘤分子标记物和生存率进行比较：我们的研究对象包括良性和恶性脑肿瘤患者（GBM = 77 例、星形细胞瘤 = 26 例、少突胶质细胞瘤 = 23 例、继发性肿瘤 = 35 例、脑膜瘤 = 70 例、许万瘤 = 15 例、垂体腺瘤 = 15 例、正常人 = 30 例）。测量时，我们使用了超灵敏电化学发光多重免疫测定法：结果：血浆GFAP浓度高与GBM相关，低GFAP和高FABP4与脑膜瘤相关，低GFAP和低FABP4与星形细胞瘤和少突胶质瘤相关。NEFL与疾病进展有关。一些预后基因改变与所有血浆生物标志物水平均有显著相关性。我们发现血浆GFAP、NEFL、FABP4和MMP3与总生存期之间没有独立关联。候选生物标志物不能可靠地区分GBM与原发性或继发性中枢神经系统淋巴瘤：结论：GFAP、NEFL、FABP4和MMP3有助于鉴别诊断和预后判断，并与胶质瘤的分子变化有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Bio Materials Chemistry-Chemistry (all)

CiteScore

9.40

自引率

2.10%

发文量

464